Gilead Sciences

Health Care  |  Biotechnology
65.01 0.66 1.03%
Stock Price | May 25, 2022, 4 p.m.
1 Follower
Bid: 64.2
Ask: 66.0
Prev. Close: 64.35
52 Week Low: 57.185
52 Week High: 74.12
PE Ratio: 17.97486
Dividend Yield: 454.0%

Company Summary

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more Read less

Recently Viewed Tickers

1 year ago
2 years ago